The company has started working on new projects:

Our company starts working on documentation for a study in endometriosis for a German company.

Smooth Drug Development prepares clinical trial documentation for a clinical study of (INN: Enoxaparin natrium) and (INN: Brinzolamide + Timolol).

The company has reached important milestones in the following projects:

• Our company received the regulator’s approval for a study in pediatrics for an international pharmaceutical company. Our Clinical team prepares to open the centers.
• In April, Smooth Clinical team closed the centers for two projects of Russian pharmaceutical companies.
• Smooth Drug Development closed the centers engaged in the clinical trial in immunodeficiency for an international company. Our team has already submitted statistical report.
• In terms of the study of (INN: Amlodipine+Bisoprolol+Perindopril) for a European company, Smooth Drug Development imported the drug and launched initiation visits.
• In April, our Clinical team closed centers for a phase three study in immunodeficiency of an international company.

The Business development team visited Generic Drug Forum 2018, which took place in Silver Spring Maryland on April 11-12. The conference was arranged by FDa and was dedicated to the AND applications. We learnt the latest news of American regulations and met many interesting researchers.

Our Business development team also visited two CPhI conference: one in Russia and another one in the USA. We compared two conferences and built new prospective relations with professional on both continents.

In the nearest future you can meet us at:

• May 20-23, MAGI Convention, Arlington, Virginia, USA
• June 1-5, ASCO, Chicago, Illinois, USA
• June 4-7, BIO America, Boston, USA